Novartis AG ADR buy melinda
Start price
25.05.19
/
50%
€79.30
Target price
04.11.21
€90.20
Performance (%)
-8.45%
End price
05.11.21
€72.60
Summary
This prediction ended on 05.11.21 with a price of €72.60. With a performance of -8.45%, the BUY prediction by melinda finished with a loss. A total of €5.57 was paid as dividends for this prediction. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Novartis AG ADR | -2.335% | -2.335% | 1.322% | 26.722% |
| iShares Core DAX® | -0.683% | 1.890% | 15.367% | 17.155% |
| iShares Nasdaq 100 | 0.335% | 4.631% | 29.818% | 56.187% |
| iShares Nikkei 225® | -1.486% | -2.361% | 7.668% | 3.633% |
| iShares S&P 500 | -0.523% | 2.324% | 25.460% | 46.452% |
Comments by melinda for this prediction
In the thread Novartis AG ADR diskutieren
NOVARTIS
Novartis AG
Cycadia (sNDA)
décision de la FDA sur Zykadia en première intention - le traitement des patients atteints de cancer du poumon métastatique non à petites cellules (NSCLC) , dont les tumeurs sont kinase lymphatique anaplasique (ALK) - positif
23/08/2017
La FDA approuve l'utilisation prolongée de Zykadia 26, mai 2017
In the thread Trading Novartis AG ADR
Die von melinda gewählte maximale Laufzeit wurde überschritten